Compare Novavax Inc (NVAX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Target Corporation — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Target Corporation trades at $138.64 (market cap $63.40B). The key difference: Target Corporation is far larger — about 48.8× Novavax Inc's market cap, and Target Corporation pays a 3.32% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TGT | |
|---|---|---|
Market Cap | $1.30B | $63.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $141.19 |
52-Week Low | $6.22 | $83.68 |
Enterprise Value | $800.50M | $78.70B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Target Corporation (TGT) trades at $138.50, down 0.8% on the day, with a bullish technical outlook supported by moving averages. The company maintains stable revenue near $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent news highlights new product collaborations and institutional buying interest, while analyst consensus leans slightly bullish with a $138.21 price target.
Target's investment case balances solid fundamentals against margin pressures. Opportunities include consistent dividend payments and market share gains in retail, but risks involve competitive pressures and potential consumer spending slowdowns. The stock offers value with a P/E of 18.44 but requires monitoring of net income margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
